Australian nuclear medicine company Telix Pharmaceuticals (ASX:TLX) has announced a collaboration with Regeneron to develop new targeted cancer treatments.
The agreement combines Telix’s established capabilities in radiopharmaceutical development, manufacturing and global supply with Regeneron’s strengths in antibody discovery and oncology research.
By integrating biologics, such as bispecific antibodies, with targeted radiation, the companies aim to create therapies that can more precisely target cancer cells while sparing healthy tissue. Alongside therapeutic development, the collaboration will also focus on diagnostic tools designed to improve patient selection and monitor treatment response, reinforcing a broader commitment to personalised oncology.
Regeneron is a US company focused on turning genetic insights into targeted therapies. Known for its VelociSuite antibody platforms, it has built leading franchises in ophthalmology, immunology, and oncology, with drugs like EYLEA (aflibercept) anchoring its portfolio.
Telix will receive an upfront payment of US$40 million covering four initial programs, with the potential to expand the collaboration further. The agreement includes a flexible model that allows Telix to either share equally in development costs and future profits or opt for milestone payments and royalties that could total up to US$2.1 billion across programs.
“The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true ‘next gen’ biologics-based radiopharmaceuticals can potentially do for patients,” said DR Christian Behrenbruch, Managing Director and Group CEO at Telix. “We are well-positioned to work toward the shared goal of advancing next-generation precision radiopharmaceuticals for patients with hard-to-treat cancers.”
“Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron’s antibody technologies and oncology portfolio,” said Dr Israel Lowy, Senior Vice President, Clinical Development Unit Head, Oncology at Regeneron. “Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care.”